Global trade tensions, supply chain disruptions, and U.S. reshoring initiatives have created unprecedented volatility in the pharmaceutical and medical device industries, driving record M&A and contract manufacturing activity. This article explains why efficient and high-quality Due Diligence (DD) and Quality Systems Integration (QSI) are critical for competitiveness, as companies that act quickly gain market advantage while slower players risk losing share.